Single-use medical devices firm Vygon Group has this week announced its acquisition of Pilot, an Italian specialist in electrocardiography guidance (ECG) devices.
The purpose of the deal is to acquire the location and navigation capabilities of Pilot’s TLS device, a product which enables precision placement of the distal tip of central venous catheters.
Vygon Group already markets the device and, following the deal, will now also handle its manufacture and future development from its production and development site in Medwin, near the French city of Montpelier.
“This new acquisition is part of our group’s external growth strategy,” said Stéphane Regnault, chief executive of Vygon. “We have been working with Pilot for the last three years. The internalisation of its ECG guidance system will enable us to consolidate our offering of intravascular therapies on the international market.”
The acquisition means Vygon will now offer international customers a comprehensive range of intravascular therapies, including implantable ports, PICC lines, midlines and central venous catheters, and the equipment to ensure their implementation, such as the TLS Pilot device.
Vygon Group distributes over 205 million products a year in over 120 countries through a network of 26 subsidiaries and 331 distributors.
The financial terms of the acquisition were not disclosed.